Compare Smith & Nephew plc (SNN) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Synchrony Financial — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while Synchrony Financial trades at $77.5 (market cap $25.58B). The key difference: Synchrony Financial is far larger — about 2.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| SNN | SYF | |
|---|---|---|
Market Cap | $11.63B | $25.58B |
Sector | Health | Financials |
52-Week High | $38.53 | $88.47 |
52-Week Low | $27.80 | $63.78 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Synchrony Financial (SYF) trades at $78.62, down 1.63% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 8.06 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings beats and a strategic partnership with OpenAI for AI-driven commerce highlight growth initiatives. Analyst consensus is bullish with a $87.33 price target and no sell ratings.
The outlook remains positive given valuation appeal, consistent earnings performance, and AI partnership potential. Key risks include consumer credit deterioration amid economic uncertainty and increased investing cash outflows. Institutional ownership trends and strong buyback activity support the bullish case, but credit quality monitoring is essential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
